Drug Profile


Alternative Names: BTA-798

Latest Information Update: 21 Apr 2017

Price : $50

At a glance

  • Originator Biota Holdings
  • Developer Aviragen Therapeutics; Biota Pharmaceuticals
  • Class Antivirals; Benzoxazoles; Small molecules
  • Mechanism of Action Rhinovirus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rhinovirus infections

Most Recent Events

  • 04 Apr 2017 Aviragen Therapeutics terminates a phase II trial, prior to enrolment, in Rhinovirus infections (in haematopoietic stem cell transplant patients) based on analysis of SPIRITUS trial data
  • 13 Feb 2017 Top-line efficacy data from phase IIb SPIRITUS trial in Rhinovirus infections released by Aviragen Therapeutics
  • 25 Jan 2017 Aviragen Therapeutics plans a phase II trial in Rhinovirus infections (NCT03024177)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top